首页> 外文OA文献 >Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

【2h】

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

机译：对多发性骨髓瘤患者，以美法仑/氟达拉滨为基础的剂量减少异体干细胞移植治疗后，先前的自体移植和慢性移植物抗宿主病复发是最强的预后因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Kröger Nicolaus; Perez-Simon Jose A.; Myint Han; Klingemann Hans; Shimoni Avichai; Nagler Arnon; Martino Rodrigo; Alegre Adrian; Tomas Jose F.; Schwerdtfeger Rainer; Kiehl Michael; Fauser Axel; Sayer Herbert Gottfried; Leon Angel; Beyer Jörg; Zabelina Tatjana; Ayuk Francis; San Miguel Jesus F.; Brand Ronald; Zander Axel Rolf;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. [J] . Kroger N, Perez Simon JA, Myint H, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2004 ,第10期

机译：对多发性骨髓瘤患者，以美法仑/氟达拉滨为基础的剂量减少异体干细胞移植治疗后，复发至先前的自体移植和慢性移植物抗宿主病是最强的预后因素。
2. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine|[sol]|melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine|[sol]|busulfan [J] . A Shimoni, I Hardan, N Shem-Tov, Leukemia . 2007 ,第10期

机译：同种异体造血干细胞移植前两种基于氟达拉滨的低强度调理方案的比较：氟达拉滨| [sol] |美法仑与急性移植物抗宿主病发病率高，非复发死亡率和复发率低相关氟达拉滨| [sol] |白消安
3. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation | Haematologica [J] . Juan Mateos-Mazon, José-Antonio Pérez-Simón, Olga Lopez, Haematologica . 2007 ,第9期

机译：硼替佐米用于异基因移植后复发的多发性骨髓瘤患者的慢性移植物抗宿主病治疗血液学
4. Symptoms, Cytokines, and Quality of Life of Patients with Chronic Graft-versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation. [D] . Kelly, Debra Lynch. 2014

机译：异基因造血干细胞移植后慢性移植物抗宿主病患者的症状，细胞因子和生活质量。
5. Dynamic International Prognostic Scoring System scores pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis [O] . Markus Ditschkowski, Ahmet H. Elmaagacli, Rudolf Trenschel, 2012

机译：动态国际预后评分系统评分移植前治疗和慢性移植物抗宿主病决定了异基因造血干细胞移植治疗骨髓纤维化的结果
6. Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma [O] . Kroger N., Perez-Simon J.A., Myint H., 2004

机译：多发性骨髓瘤患者美法仑/氟达拉滨减量同种异体干细胞移植的危险因素

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

著录项

相似文献

相关主题

期刊订阅